Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Eklira Genuair 322 micrograms inhalation powder

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Aclidinium bromide may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Aclidinium bromide
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for

What Eklira Genuair is The active ingredient of Eklira Genuair is aclidinium bromide, which belongs to a group of medicines called bronchodilators. Bronchodilators relax airways and help keep bronchioles open. Eklira Genuair is a dry powder inhaler that uses your breath to deliver the medicine directly into your lungs. This makes it easier for chronic obstructive pulmonary disease (COPD) patients to breathe. What Eklira Genuair is used for Eklira Genuair is indicated to help open the airways and relieve symptoms of COPD, a serious, longterm lung disease characterised by breathing difficulties. Regular use of Eklira Genuair can help you when you have ongoing shortness of breath related to your disease to help you minimise the effects of the disease on your everyday life and reduce the number of flare-ups (the worsening of your COPD symptoms for several days). 2.

What you need to know before you take it

e Eklira Genuair

Do not use Eklira Genuair

  • if you are allergic to aclidinium bromide or any of the other ingredients of this medicine (listed in section 6). Warnings and precautions Talk to your doctor, pharmacist or nurse before using Eklira Genuair: if you have heart problems. if you see halos around lights or coloured images (glaucoma). if you have an enlarged prostate, problems passing urine, or a blockage in your bladder. Eklira Genuair is indicated for maintenance treatment and should not be used to treat a sudden attack of breathlessness or wheezing. If your COPD symptoms (breathlessness, wheezing, cough) do not improve or get worse you should contact your doctor for advice as soon as possible.

Dry mouth, which has been observed with medicines like Eklira Genuair, may after using your medicine for a long time, be associated with tooth decay. Therefore, please remember to pay attention to oral hygiene. Stop taking Eklira Genuair and seek medical help immediately: if you get tightness of the chest, coughing, wheezing or breathlessness immediately after using the medicine. These may be signs of a condition called bronchospasm. Children and adolescents Eklira Genuair is not for use in children or adolescents below 18 years of age. Other medicines and Eklira Genuair Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Inform your doctor if you have been or are using similar medicines for breathing problems, such as medicines containing tiotropium, ipratropium. Ask your doctor or pharmacist if you are not sure. The use of Eklira Genuair with these medicines is not recommended. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not use Eklira Genuair if you are pregnant or are breast-feeding unless your doctor tells you so. Driving and using machines Eklira Genuair may have minor influence on the ability to drive and use machines. This medicine may cause headache, dizziness or blurred vision. If you are affected by any of these side effects do not drive or use machinery until the headache has cleared, the feeling of dizziness has passed and your vision has returned to normal. Eklira Genuair contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 3.

How to use Eklira Genuair

Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The recommended dose is one inhalation twice a day in the morning and evening. The effects of Eklira Genuair last for 12 hours; therefore, you should try to use your Eklira Genuair inhaler at the same time every morning and evening. This ensures that there is always enough medicine in your body to help you breathe more easily throughout the day and night. It will also help you to remember to use it. The recommended dose can be used for elderly patients and for patients with kidney or liver problems. No dose adjustments are necessary. COPD is a long-term disease; therefore, it is recommended that Eklira Genuair is used every day, twice a day and not only when breathing problems or other symptoms of COPD are experienced. Route of administration The medicine is for inhalation use. Refer to Instructions for Use for instructions on how to use the Genuair inhaler. If you are not sure of

How to take it

Eklira Genuair, contact your doctor or pharmacist.

You can use Eklira Genuair any time before or after food or drink. If you use more Eklira Genuair than you should If you think you may have used more Eklira Genuair than you should, contact your doctor or pharmacist. If you forget to use Eklira Genuair If you forget a dose of Eklira Genuair, inhale the dose as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose. Do not take a double dose to make up for a forgotten dose. If you stop using Eklira Genuair This medicine is for long-term use. If you want to stop treatment, first talk to your doctor, as your symptoms may worsen. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Allergic reactions may rarely occur (may affect up to 1 in 1,000 people). Stop using the medicine and contact your doctor immediately if you develop swelling of your face, throat, lips or tongue (with or without difficulty breathing or swallowing), dizziness or fainting, faster heart rate or if you get raised severely itchy bumps on your skin (hives) as these may be symptoms of an allergic reaction. The following side effects may occur whilst using Eklira Genuair: Common: may affect up to 1 in 10 people

  • Headache
  • Inflammation of the sinuses (sinusitis)
  • Common cold (nasopharyngitis)
  • Cough
  • Diarrhoea
  • Nausea Uncommon: may affect up to 1 in 100 people
  • Dizziness
  • Dry mouth
  • Inflammation of the mouth (stomatitis)
  • Hoarseness (dysphonia)
  • Faster heart beat (tachycardia)
  • Sensation of heart beating (palpitations)
  • Abnormal or irregular heartbeat (cardiac arrhythmias)
  • Difficulty passing urine (urinary retention)
  • Blurred vision
  • Rash
  • Itching of the skin Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5.

How to store it

Eklira Genuair

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the inhaler label and carton after "EXP". The expiry date refers to the last day that month. Keep the inhaler inside the pouch until the administration period starts. To be used within 90 days of opening the pouch. Do not use the Eklira Genuair if you notice that the pack is damaged or shows signs of tampering. After you have taken the last dose, the inhaler has to be disposed of. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6.

Contents of the pack and other information

What Eklira Genuair contains The active substance is aclidinium bromide. Each delivered dose contains 375 micrograms aclidinium bromide equivalent to 322 micrograms of aclidinium. The other ingredient is lactose monohydrate (refer to Section 2 "Eklira Genuair contains lactose"). What Eklira Genuair looks like and contents of the pack Eklira Genuair is a white or almost white powder. The Genuair inhaler device is white coloured with an integral dose indicator and a green dosage button. The mouthpiece is covered with a removable green protective cap. It is supplied in a plastic pouch. Pack sizes supplied: Carton containing 1 inhaler with 30 doses. Carton containing 1 inhaler with 60 doses. Carton containing 3 inhalers each with 60 doses. Not all pack sizes may be marketed. Marketing Authorisation Holder Azurity Pharmaceuticals Ireland Ltd. The Observatory 7-11 Sir John Rogerson's Quay Dublin 2, D02 VC42 Ireland Manufacturer Industrias Farmacéuticas Almirall, S.A. Ctra. de Martorell 41-61 08740 Sant Andreu de la Barca, Barcelona Spain This leaflet was last revised in July 2026.

Other sources of information

To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 08004334029 (UK only) Please be ready to give the following information: Product name Eklira Genuair 322 micrograms inhalation powder

Reference number PL 60277/0004

This is a service provided by the Royal National Institute of the Blind. Instructions for Use This section contains information on how to use your Genuair inhaler. It is important that you read this information as the Genuair may work differently from inhalers you have used previously. If you have any questions about how to use your inhaler, please ask your doctor, pharmacist or nurse for assistance. The Instructions for Use is divided into the following sections:

  • Getting started
  • Step 1: Prepare your dose
  • Step 2: Inhale your medicine
  • Additional information Getting Started Read these Instructions for Use before you start using the medicine. Become familiar with the parts of your Genuair inhaler.

Control window Green = inhaler ready to use

Dose indicator

Protective Cap

Green button

Control window Red = confirms correct inhalation Mouthpiece

Figure A

Before use: a) Before first use, tear open the sealed bag and remove the inhaler. Throw away the bag. b) Do not press the green button until you are ready to take a dose. c) Pull off the cap by lightly squeezing the arrows marked on each side (Figure B).

Squeeze here and pull

Figure B STEP 1: Prepare your dose 1.1 Look in the opening of the mouthpiece and make sure nothing is blocking it (Figure C). 1.2 Look at the control window (should be red, Figure C). RED

Check mouthpiece opening Figure C 1.3 Hold the inhaler horizontally with the mouthpiece facing you and the green button on top (Figure D).

Figure D 1.4 Press the green button all the way down to load your dose (Figure E). When you press the button all the way down, the control window changes from red to green.

Make sure the green button is on top. Do not tilt. 1.5 Release the green button (Figure F). Make sure you release the button so the inhaler can work correctly.

Figure E

Figure F

Stop and Check: 1.6 Make sure the control window is now green (Figure G). Your medicine is ready to be inhaled. Go to 'STEP 2: Inhale your medicine'. GREEN

Figure G What to do if the control window is still red after pressing the button (Figure H).

Figure H The dose is not prepared. Go back to 'STEP 1 Prepare your dose' and repeat steps 1.1 to 1.6.

STEP 2: Inhale your medicine Read steps 2.1 to 2.7 fully before use. Do not tilt. 2.1 Hold the inhaler away from your mouth, and breathe out completely. Never breathe out into the inhaler (Figure I).

Figure I 2.2 Hold your head upright, put the mouthpiece between your lips, and close your lips tightly around it (Figure J). Do not hold the green button down while inhaling.

Figure J 2.3 Take a strong, deep breath through your mouth. Keep breathing in for as long as possible. A 'click' will let you know that you are inhaling correctly. Keep breathing in as long as possible after you hear the 'click'. Some patients may not hear the 'click'. Use the control window to ensure you have inhaled correctly. 2.4 Take the inhaler out of your mouth. 2.5 Hold your breath for as long as possible. 2.6 Slowly breathe out away from the inhaler. Some patients may experience a grainy sensation in their mouth, or a slightly sweet or bitter taste. Do not take an extra dose even if you do not taste or feel anything after inhaling. Stop and Check: 2.7 Make sure the control window is now red (Figure K). This means you have inhaled your medicine correctly.

RED

Figure K What to do if the control window is still green after inhalation (Figure L).

Figure L This means you have not inhaled your medicine correctly. Go back to 'STEP 2 Inhale your medicine' and repeat steps 2.1 to 2.7. If the control window still does not change to red, you may have forgotten to release the green button before inhaling, or you may not have inhaled strongly enough. If this happens, try again. Make sure you have released the green button, and you have breathed out completely. Then take a strong, deep breath through the mouthpiece. Please contact your doctor if the control window is still green after repeated attempts. Push the protective cap back onto the mouthpiece after each use (Figure M), to prevent contamination of the inhaler with dust or other materials. You should discard your inhaler if you lose the cap.

Figure M Additional information

What should you do if you accidently prepare a dose? Store your inhaler with the protective cap in place until it is time to inhale your medicine, then remove the cap and start at Step 1.6. How does the dose indicator work?

  • The dose indicator shows the total number of doses left in the inhaler (Figure N).
  • On first use, every inhaler contains at least 60 doses, or at least 30 doses, depending on the pack size.
  • Each time you load a dose by pressing the green button, the dose indicator moves by a small amount towards the next number (50, 40, 30, 20, 10, or 0). When should you get a new inhaler? You should get a new inhaler:
  • If your inhaler appears to be damaged or if you lose the cap, or
  • When a red band appears in the dose indicator, this means you are nearing your last dose (Figure N), or
  • If your inhaler is empty (Figure O). Dose indicator moves slowly from 60 to 0: 60, 50, 40, 30, 20, 10, 0. Dose indicator

Red band

Figure N How do you know that your inhaler is empty? When the green button will not return to its full upper position and is locked in a middle position, you have reached the last dose (Figure O). Even though the green button is locked, your last dose may still be inhaled. After that, the inhaler cannot be used again and you should start using a new inhaler.

Locked

Figure O

How should you clean the inhaler? NEVER use water to clean the inhaler, as this may damage your medicine. If you wish to clean your inhaler, just wipe the outside of the mouthpiece with a dry tissue or paper towel.

Frequently asked questions about Eklira Genuair 322 micrograms inhalation powder

How do I take Eklira Genuair 322 micrograms inhalation powder?

Eklira Genuair 322 micrograms inhalation powder comes as inhaler containing 322mcg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Eklira Genuair 322 micrograms inhalation powder?

The active substance in Eklira Genuair 322 micrograms inhalation powder is aclidinium bromide.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Eklira Genuair 322 micrograms inhalation powder, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Eklira Genuair 322 micrograms inhalation powder without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Aclidinium bromide (2 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD) (see section 5.1).

4.2. Posology and method of administration

Posology

The recommended dose is one inhalation of 322 micrograms aclidinium twice daily.

If a dose is missed the next dose should be taken as soon as possible. However, if it is nearly time for the next dose, the missed dose should be skipped.

Elderly

No dose adjustments are required for elderly patients (see section 5.2).

Renal impairment

No dose adjustments are required for patients with renal impairment (see section 5.2).

Hepatic impairment

No dose adjustments are required for patients with hepatic impairment (see section 5.2).

Paediatric population

There is no relevant use of Eklira Genuair in children and adolescents (under 18 years of age) for the indication of COPD.

Method of administration

For inhalation use.

Patients should be instructed on how to administer the product correctly as the Genuair inhaler may work differently from inhalers the patients may have used previously. It is important to instruct the patients to carefully read the Instructions for Use in the Package Leaflet, which is packed together with each inhaler.

For Instructions for Use, see section 6.6.

4.3. Contraindications

Hypersensitivity to aclidinium bromide or to the excipients listed in section 6.1.

4.4. Special warnings and precautions for use

Paradoxical bronchospasm:

Administration of Eklira Genuair may cause paradoxical bronchospasm. If this occurs, treatment with Eklira Genuair should be stopped and other treatments considered.

Deterioration of disease:

Aclidinium bromide is a maintenance bronchodilator and should not be used for the relief of acute episodes of bronchospasm, i.e. as a rescue therapy. In the event of a change in COPD intensity while the patient is being treated with aclidinium bromide so that the patient considers additional rescue medication is required, a re-evaluation of the patient and the patients' treatment regimen should be conducted.

Cardiovascular effects:

Cardiac arrhythmias, including atrial fibrillation and paroxysmal tachycardia were seen after the administration of Eklira Genuair (see section 4.8). Therefore, Eklira Genuair should be used with caution in patients with cardiac arrhythmias, a history of cardiac arrhythmias or with risk factors for cardiac arrhythmias.

Experience in patients with cardiovascular comorbidities in clinical trials is limited (see section 5.1). These conditions may be affected by the anticholinergic mechanism of action.

Anticholinergic activity:

Dry mouth, which has been observed with anticholinergic treatment, may in the long term be associated with dental caries.

Consistent with its anticholinergic activity, aclidinium bromide should be used with caution in patients with symptomatic prostatic hyperplasia or bladder-neck obstruction or with narrow-angle glaucoma (even though direct contact of the product with the eyes is very unlikely).

Excipients:

This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

4.5. Interaction with other medicinal products and other forms of interaction

Co-administration of aclidinium bromide with other anticholinergic-containing medicinal products has not been studied and is not recommended.

Although no formal in vivo drug interaction studies have been performed, inhaled aclidinium bromide has been used concomitantly with other COPD medicinal products including sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids without clinical evidence of drug interactions.

In vitro studies have shown that aclidinium bromide or the metabolites of aclidinium bromide at the therapeutic dose are not expected to cause interactions active substances that are substrates of P-glycoprotein (P-gp), or active substances metabolised by cytochrome P450 (CYP450) enzymes and esterases (see section 5.2).

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no data available on the use of aclidinium bromide in pregnant women.

Studies in animals have shown foetotoxicity only at dose levels much higher than the maximum human exposure to aclidinium bromide (see section 5.3). Aclidinium bromide should only be used during pregnancy if the expected benefits outweigh the potential risks.

Breast-feeding

It is unknown whether aclidinium bromide/metabolites are excreted in human milk. Animal studies have shown excretion of small amounts of aclidinium bromide/metabolites into milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Eklira Genuair therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.

Fertility

Studies in rats have shown slight reductions in fertility only at dose levels much higher than the maximum human exposure to aclidinium bromide (see section 5.3). It is considered unlikely that aclidinium bromide administered at the recommended dose will affect fertility in humans.

4.7. Effects on ability to drive and use machines

Aclidinium bromide may have minor influence on the ability to drive and use machines. The occurrence of headache, dizziness or blurred vision following administration of aclidinium bromide (see section 4.8) may influence the ability to drive or to use machinery.

4.8. Undesirable effects

Summary of the safety profile

The most frequently reported adverse reactions with Eklira Genuair were headache (6.6%) and nasopharyngitis (5.5%).

Tabulated summary of adverse reactions

The frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse reactions (i.e. events attributed to Eklira Genuair) observed with Eklira Genuair 322 µg (636 patients) in the pooled analysis of one 6-month and two 3-month randomised, placebo-controlled clinical trials or on post-marketing study results.

A placebo-controlled trial in 1791 patients with moderate to very severe COPD treated with Eklira Genuair up to 36 months did not identify other adverse reactions.

The frequency of adverse reactions is defined using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from the available data).

System organ class

Preferred term

Frequency

Infections and infestations

Sinusitis

Common

Nasopharyngitis

Common

Immune system disorders

Hypersensitivity

Rare

Angioedema

Not known

Anaphylactic reaction

Not known

Nervous system disorders

Headache

Common

Dizziness

Uncommon

Eye disorders

Blurred vision

Uncommon

Cardiac disorders

Cardiac arrhythmias, including atrial fibrillation and paroxysmal tachycardia

Uncommon

Tachycardia

Uncommon

Palpitations

Uncommon

Respiratory, thoracic and mediastinal disorders

Cough

Common

Dysphonia

Uncommon

Gastrointestinal disorders

Diarrhoea

Common

Nausea

Common

Dry mouth

Uncommon

Stomatitis

Uncommon

Skin and subcutaneous tissue disorders

Rash

Uncommon

Pruritus

Uncommon

Renal and urinary disorders

Urinary retention

Uncommon

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

High doses of aclidinium bromide may lead to anticholinergic signs and symptoms.

However, single inhaled doses up to 6,000 µg aclidinium bromide have been administered to healthy subjects without systemic anticholinergic adverse reactions. Additionally, no clinically relevant adverse reactions were observed following 7-day twice daily dosing of up to 800 µg aclidinium bromide in healthy subjects.

Acute intoxication by inadvertent medicinal product ingestion of aclidinium bromide is unlikely, due to its low oral bioavailability and the breath-actuated dosing mechanism of the Genuair inhaler.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

⚠ Not the same combination. This medicine contains Aclidinium bromide. The products below do not contain exactly the same set of active substances — they are not direct substitutes.

  • BRIMICA GENUAIR 340 micrograme/12 micrograme prescription partial — not the same combinationACLIDINIUM BROMIDUM+FORMOTEROLUM FUMARAT · inhaler / nebuliser
  • DUAKLIR GENUAIR 340 micrograme/12 micrograme prescription partial — not the same combinationACLIDINIUM BROMIDUM+FORMOTEROLUM FUMARAT · inhaler / nebuliser

Some of these do not contain exactly the same active substances — check each one. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • Eklira GenuairAclidinii bromidum · inhaler / nebuliser
  • Bretaris GenuairAclidinii bromidum · inhaler / nebuliser

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Eklira Genuair 322 micrograms inhalation powder. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →